FCR versus BR in frontline CLL - Dr Sharman's comments on the upcoming German CLL10 ASH paper

FCR versus BR in frontline CLL - Dr Sharman's comments on the upcoming German CLL10 ASH paper

Dr Sharman says in his latest blog "The abstract I have been most eager to review in this years ASH meeting details the results of the German CLL10 study in which FCR (fludarabine, cyclophosphamide, rituximab) is compared to BR (bendamustine, rituximab) in the front line management of patients with symptomatic CLL"

Those of us nearing treatment are also eager to learn what this study has discovered!

Read more at:

cll-nhl.com/2013/11/fcr-ver...

Hopefully BR or even better BR+? will soon be available for those of us where FCR is perhaps not the better choice due to our age or other factors such as renal function and medical comorbidities.

Neil

Last edited by

1 Reply

oldestnewest
  • Thanks so much for this, Neil (and Dr Sharman). I had been struggling to get the main points from the original article myself, yesterday, but Dr Sharman's summary makes things MUCH clearer. The choice still isn't that simple, especially for those of us aged around 65 and approaching treatment, but this helps a lot.

You may also like...